Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pulmonary embolism in acute lymphoblastic leukemia - An observational study of 1685 patients treated according to the NOPHO ALL2008 protocol

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Management of Asparaginase Toxicity in AYAs with ALL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (Protocol)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ruta Tuckuviene
  • Cecilie Lundgaard Bjerg
  • Olafur Gisli Jonsson
  • Satu Langstrom
  • Cecilie Utke Rank
  • Susanna Ranta
  • Kadri Saks
  • Sonata Saulyte Trakymiene
  • Ellen Ruud
Vis graf over relationer

Background: Pulmonary embolism (PE) is a serious complication of acute lymphoblastic leukemia (ALL). We examined the cumulative incidence and clinical presentation of PE in a well-defined cohort of patients with ALL aged 1-45 years treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.

Methods: As part of the mandatory toxicity reporting of NOPHO ALL2008, thromboembolism including PE was reported consecutively. The cumulative incidence of first-time PE was calculated using the Aalen-Johansen estimator during a 2.5-year period from ALL diagnosis. We used Fisher's exact test to examine categorical variables and Cox logistic regression to estimate hazard ratios (HRs) for PE.

Results: PE was diagnosed in 32 of 1685 patients. The 2.5-year cumulative incidence of first-time PE increased with age: 0.43% (95% CI, 0.18-1.03) in children aged 1-9 years, 3.28% (95% CI, 1.72-6.22) in children aged 10-17 years, and 7.22% (95% CI, 4.61-11.21) in adults aged 18-45 years. The majority of PEs, 78% (25/32), occurred during asparaginase treatment. HRs adjusted for age and sex were associated with male sex (HR, 2.4; 95% CI, 1.0-5.6) and older age (10-17 years: HR 7.5; 95% CI, 2.5-22.2), 18-45 years: HR, 16.5; 95% CI, 6.1-44.5). In two-thirds of the patients (63%; 17/27), PE and its treatment had no impact on the administered doses of asparaginase. PE-associated 30-day mortality was 9.4% (95% CI, 1.9-25.0).

Conclusions: Awareness of PE is warranted during ALL treatment. Larger multicenter studies are needed to examine predictors of PE in ALL.

OriginalsprogEngelsk
TidsskriftResearch and practice in thrombosis and haemostasis
Vol/bind4
Udgave nummer5
Sider (fra-til)866-871
ISSN2475-0379
DOI
StatusUdgivet - jul. 2020

Bibliografisk note

© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

ID: 60517756